SABCS 2022 | Ultra-high dose rate radiation (FLASH)

Frederick Dirbas, MD, Stanford University School of Medicine, Stanford, CA, provides an overview of ultra-high dose rate radiation (FLASH) compared to conventional radiotherapy. Flash has been shown to induce less normal tissue toxicity. In this study, a murine model of breast cancer demonstrated FLASH is as effective as conventional radiotherapy in controlling tumor growth. Future studies will extend the evaluation of the tumor control using clinically relevant fractionated dose schedules to be followed by comparisons of tumor control in xenograft models. Additional studies will assess normal tissue toxicity of FLASH versus conventional radiotherapy in murine models of implant-based breast reconstruction. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.